Juno Therapeutics

Hans Bishop served as CEO from founding in 2013 through the acquisition. The venture investors, including Arch Venture Partners and Flagship Ventures, held board seats and influenced strategic funding decisions (per SEC filings, 2014).

Juno's pipeline originated from licensed technologies from the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering, and Seattle Children's Hospital, under an academic-industry consortium (per public record, 2013).

Juno was a publicly traded biotechnology corporation, not a family office. It raised a $265M IPO in 2014 and operated as a Delaware corporation, with venture capital and public shareholders providing capital (per SEC S-1 filing, 2014).

Juno targeted drug development from preclinical research through Phase 2 clinical trials. It did not act as an investor but as a biotech firm conducting clinical-stage work (per FDA clinical trial registries).

Juno focused exclusively on oncology cell therapies and did not materially engage in other therapeutic areas, medical devices, or diagnostics (per clinical trial data).

Juno Therapeutics as a public company operated without disclosed separate philanthropic foundations. Its research collaborations with academic centers might have involved charitable donations, but no dedicated foundation is public (per SEC filings).

Juno entered into co-development and licensing agreements, including a 2015 deal with Editas Medicine for engineered T-cell therapies, and a 2016 research collaboration with AstraZeneca (per public record, 2015-2016).